It was observed that CXCL13 (3,17x) and PEG10 (9,38x and 4,38x, p = 0,05) were both up-regulated in progressive disease and possibly this up-regulation can contribute to impairment of the T-lymphocyte mediated anti-tumor response in progressive disease. This evidence concerns the gene CXCL13 and neoplasm.